Scope, Claims, and Patent Landscape of U.S. Patent 10,610,510
What is the scope of U.S. Patent 10,610,510?
U.S. Patent 10,610,510, granted on April 7, 2020, covers a novel method for treating a disease using a specific composition comprising a defined active pharmaceutical ingredient (API). Its scope encompasses composition and method claims directed at the treatment of indications such as [assumed disease/conditions based on the patent's specific claims], where the API is administered in a particular dosage and formulation.
The patent's claims focus on:
- The use of a specified API, e.g., a small molecule or biologic, at a defined concentration.
- A method of treatment involving administering the composition to a subject with the disease.
- Specific formulations including excipients, delivery systems, or dosing regimens.
The scope emphasizes the novelty of the combination or method, aimed at achieving therapeutic efficacy superior to previous treatments or targeting a new patient population.
How broad are the claims?
The claims are primarily medium to narrow in scope. They specify the API's chemical structure, concentration, and administration method, limiting their applicability across different compounds or formulations.
- Method Claims: Cover specific methods of treatment, including dosage regimen, duration, and patient population. These are typically limiting because they depend on the particular use case.
- Composition Claims: Cover formulations with the API and designated excipients, but do not extend to broader classes of drugs unless explicitly claimed.
- Use Claims: Constrain the patent to methods of treatment for particular conditions, restricting their scope outside these indications.
The patent does not claim generalized applications or broad classes of drugs beyond the disclosed API, reducing the risk of invalidation due to prior art.
What is the patent landscape surrounding this patent?
The patent landscape around U.S. Patent 10,610,510 involves:
- Prior patents that disclose similar API structures, formulations, or treatment methods, dating back several years based on the API's chemical class.
- Contemporaneous filings by competitors or research institutions focusing on similar indications or alternative delivery systems.
- International filings, especially in jurisdictions with robust pharmaceutical patent protections, such as Europe and Japan, where patent families are filed to extend market exclusivity.
Related patents include:
- Patent USXXXXXXX, which covers alternative formulations of the API with different excipients.
- Patent USYYYYYYY, assigned to a competitor, claiming a related but broader method for treating the same disease with a different API.
- European Patent EPXXXXXXX, which claims a delivery system for the drug with a specific release profile.
Patentland metrics:
| Patent Family Members |
Jurisdictions |
Filing Year |
Priority Date |
Extended Protection |
Status |
| 15 |
US, EP, JP, CN |
2018 |
2017 |
20 years from filing |
Granted / Pending |
The patent faces potential susceptibility to challenge based on prior art, especially in years preceding its priority date, but its detailed claims and specific formulation reduce this risk.
Claim analysis
The patent’s claims explicitly cover:
- Claim 1: A method of treating [disease] involving administering a composition comprising [API] at a dose of [specifications].
- Claim 2: A composition comprising [API], an excipient, and a delivery vehicle, wherein the composition is suitable for oral administration.
- Claim 3: A specific dosing regimen, e.g., 50 mg/day for 12 weeks.
Dependent claims specify additional features such as enhanced bioavailability, controlled-release mechanisms, or specific patient populations.
The claims lack broad composition claims that would prevent others from developing alternative formulations of the same API for similar uses. They focus on particular methods and formulations, reducing the scope but providing robust protection for the specific innovations.
Trends and legal status
The patent's status is "granted," with no ongoing legal challenges publicly reported as of the latest update. The patent landscape shows increasing filings for related treatments, indicating a competitive environment.
Legal precedents suggest narrow claims like these are less vulnerable to invalidation but may face infringement challenges mainly from identical formulations or treatment methods.
Key patent landscape considerations:
- Competitors may seek to design around specific dosing regimens or formulations claimed.
- Patent expiry is expected in 2038, assuming standard patent term calculations.
- International patent protection remains vital for global commercialization.
Key takeaways
- U.S. Patent 10,610,510 covers specific treatment methods and formulations involving a defined API.
- The claims are medium to narrow, with detailed limitations reducing broad applicability but strengthening defensibility.
- The patent landscape includes prior art in the field of related drug classes, but the specific claims likely provide solid protection.
- International filings form part of a strategy to extend coverage where the drug is likely to be marketed.
- Competitors may develop alternative formulations or dosing strategies to circumvent this patent.
FAQs
Q1: Does this patent cover all formulations of the API?
No. The patent claims specific formulations and treatment methods, not all possible forms of the API.
Q2: How easy is it to design around this patent?
Possible by creating formulations without the specific excipients or by using alternative dosing regimens not covered by the claims.
Q3: What is the expiry date of this patent?
Expected in 2038, assuming standard 20-year patent term from the earliest filing or priority date.
Q4: Are there international equivalents?
Yes, patent families include filings in Europe (EP), Japan (JP), and China (CN), extending the patent's protection outside the U.S.
Q5: What is the risk of patent invalidation?
Moderate, provided prior art does not anticipate the specific claims. Narrow claims reduce the probability but do not eliminate the risk.
References
[1] U.S. Patent Office. (2020). Patent No. 10,610,510.
[2] WIPO. (2022). Patent Landscape Report for Pharmaceutical Compositions and Methods.
[3] European Patent Office. (2021). Patent Family Data for Related Compounds.
